title: Intralesional interferon-alpha 2b treatment of basal cell carcinoma.
abstract: Ten patients with histologically proven basal cell carcinoma were treated with sublesional injections of interferon-alpha 2 b (Introna), 1.5 x 10(6) units per injection, three times per week for 3 weeks. Six of the treated lesions cleared completely without further therapy. These lesions measured less than 19 x 19 mm. There was no relapse during an observation period of up to 21 months. Non-healing tumours were large (greater than 20 x 20 mm) and two of them were of nodular type. Side effects were negligible, if present at all. Introna seems to offer a valuable alternative treatment for selected cases of basal cell carcinoma, when excision or X-ray therapy cannot be performed.
authors.affiliation: Department of Dermatology, Marselisborg Hospital, Aarhus, Denmark.
authors.forename: K
authors.initials: K
authors.lastname: Thestrup-Pedersen
authors.forename: I E
authors.initials: IE
authors.lastname: Jacobsen
authors.forename: G
authors.initials: G
authors.lastname: Frentz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002280:Basal Cell Carcinoma / Q000628:therapy*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000628:therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins